For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Nichiiko: Branded Generic Business Boosts Sales, Profits
February 4, 2002
- Takeda Expects 2002 to Be Year of Implementation: President
February 4, 2002
- WORLD NEWS IN BRIEF
February 4, 2002
- Fukujin to Be Listed on TSE
February 4, 2002
- Elderly Patients Should Settle Accounts with Their Insurers
February 4, 2002
- Sanuki, Ohmori Yakuhin Shikoku, Baikado to Form Koyo on April 1
February 4, 2002
- Daiwa, Kowa to Tie Up in Shikoku
February 4, 2002
- Medical Fee Reduction to Seriously Hit Medical Institutions: JMARI
February 4, 2002
- Vital-Net, Ohmori Yakuhin Tohoku Postpone Merger
February 4, 2002
- BULLETIN
February 4, 2002
- Telmisartan to Be Copromoted by NBI, Yamanouchi
February 4, 2002
- Korosho's Preparations for NHI Price Revision Delay
February 4, 2002
- WEBSITE NEWS
February 4, 2002
- Ordinary Session of Diet to Deal with Budgets
February 4, 2002
- BUSINESS NEWS IN BRIEF
February 4, 2002
- New Chugai to Achieve \300 Bil. in FY2005: Mr Ogawa of Nippon Roche
February 4, 2002
- OTC NEWS IN BRIEF
February 4, 2002
- Marketing Approval System Could Harm Local Industry: Diet Member Fujii
February 4, 2002
- Addition of 10 Medical Specialties Requested of Korosho
February 4, 2002
- Economic Incentives to Be Given to Promote Use of Generics
February 4, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…